Therapy Areas: Respiratory
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
14 August 2025 - Nanjing Leads Biolabs Co, Ltd (9887.HK) announced on Thursday that it has completed patient enrollment in its pivotal single-arm registrational trial (CTR20213023) evaluating Opamtist...
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
14 August 2025 - BioDlink, a China-based pharmaceutical company, announced on Wednesday that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia's Na...
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
13 August 2025 - Insmed Incorporated (Nasdaq: INSM), a US-based global biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved first-in-class BRINSU...
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis
11 August 2025 - Pharmaceutical development company Nuformix plc (LSE:NFX) declared on Monday that it has submitted an application to the US Food and Drug Administration for Orphan Drug Designation (O...
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
11 August 2025 - Akeso Inc (9926.HK) a China-based pharmaceutical company, announced on Sunday that the first patient has been dosed in its multicentre, randomised, double-blind Phase III study (AK112...
Cipla expands Fall River operations, announces recruitment drive
8 August 2025 - Cipla Limited (BSE: 500087) (NSE: CIPLA EQ), an India-based pharmaceutical company, announced on Thursday a significant expansion of its manufacturing facility located at Innovation Wa...